Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 19/20 | 0.68 |
| ▸ | SLC5A1 | P13866 | 17/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29572195 | 1.00 | SLC5A2 (0.68) | SLC5A2SLC5A1NPC1RAB9A | |
| SCHEMBL22716935 | 1.00 | SLC5A2 (0.68) | SLC5A2SLC5A1NPC1RAB9A | |
| SCHEMBL4359584 | 0.92 | SLC5A2 (0.68) | SLC5A2SLC5A1NPC1RAB9A | |
| SCHEMBL5383101 | 0.85 | SLC5A2 (0.69) | SLC5A2SLC5A1 | |
| SCHEMBL4000126 | 0.82 | SLC5A2 (0.64) | SLC5A2SLC5A1NPC1RAB9A | |
| SCHEMBL4000120 | 0.82 | SLC5A2 (0.64) | SLC5A2SLC5A1NPC1RAB9A | |
| SCHEMBL4350692 | 0.82 | SLC5A2 (0.67) | SLC5A2SLC5A1 | |
| SCHEMBL2252419 | 0.81 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| SCHEMBL4358723 | 0.81 | SLC5A2 (0.58) | SLC5A2SLC5A1 | |
| SCHEMBL5381328 | 0.80 | SLC5A2 (0.57) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114450011-A | Compositions and methods for treating metabolic disorders | 阿沃林特有限公司 | 2022-05-06 | — | — | CN | disclosed |
| EP-1782828-B1 | PROGRESSION INHIBITOR FOR DISEASE ATTRIBUTED TO ABNORMAL ACCUMULATION OF LIVER FAT | KISSEI PHARMACEUTICAL (JP) | 2016-06-29 | — | — | EP | disclosed |
| US-8951976-B2 | Progression inhibitor for disease attributed to abnormal accumulation of liver fat | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-20090286751-A1 | PROGRESSION INHIBITOR FOR DISEASE ATTRIBUTED TO ABNORMAL ACCUMULATION OF LIVER FAT | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20080045466-A1 | Progression Inhibitor For Disease Attributed To Abnormal Accumulation Of Liver Fat | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-02-21 | — | — | US | disclosed |
| US-7271153-B2 | Treating diseases associated with hyperglycemia such as diabetes; SGLT2 (sodium/glucose cotransporter 2) inhibitor; 3-(4-Ethylbenzyl)-2-(beta-D-glucopyranosyloxy)-4,6-dimethyl-pyridine for example | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-18 | — | — | US | disclosed |
| EP-1782828-A1 | PROGRESSION INHIBITOR FOR DISEASE ATTRIBUTED TO ABNORMAL ACCUMULATION OF LIVER FAT | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-05-09 | — | — | EP | disclosed |
| EP-1405859-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATE THEREFOR | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045466-A1 | Progression Inhibitor For Disease Attributed To Abnormal Accumulation Of Liver Fat | SLC10A1, SLC2A2, SLC2A1 | SLC5A2 10/4885SLC5A1 12/4885NPC1 47/4885 |
| US-20090286751-A1 | PROGRESSION INHIBITOR FOR DISEASE ATTRIBUTED TO ABNORMAL ACCUMULATION OF LIVER FAT | FABP1, SLC2A1, SLC10A1 | SLC5A2 11/4885SLC5A1 15/4885NPC1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.